Intra-Cellular Therapies (FRA:23I) ROCE % : -13.80% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Intra-Cellular Therapies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Intra-Cellular Therapies's annualized ROCE % for the quarter that ended in Mar. 2024 was -13.80%.

Intra-Cellular Therapies ROCE % Historical Data

The historical data trend for Intra-Cellular Therapies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies ROCE % Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-58.30

-50.50

-53.47

-48.78

-24.59

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-29.30	-29.68	-19.38	-22.13	-13.80

Intra-Cellular Therapies ROCE % Calculation

Intra-Cellular Therapies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-146.152	/	( ( (712.512 - 78.575)	+	(667.847 - 113.291) )	/ 2 )
	=	-146.152	/	( (633.937	+	554.556)	/ 2 )
	=	-146.152	/	594.2465
	=	-24.59 %

Intra-Cellular Therapies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-77.104	/	( ( (667.847 - 113.291)	+	(687.273 - 124.017) )	/ 2 )
	=	-77.104	/	( ( 554.556	+	563.256 )	/ 2 )
	=	-77.104	/	558.906
	=	-13.80 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Intra-Cellular Therapies (FRA:23I) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Intra-Cellular Therapies ROCE % Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (FRA:23I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (FRA:23I) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (FRA:23I) Headlines

No Headlines